On the other hand, special attention has been paid to anti-vascular endothelial growth factor (VEGF) drugs, such as ranibizumab monoclonal antibody, for the treatment of ocular diseases, including diabetes-induced retinopathy and age-related macular degeneration (AMD) due to angiogenesis. Here, VEGFA is linked to age-related macular degeneration.